7 RESULTS
COMMENT Fundamental questions about the efficacy of donanemab (and also lecanemab) remain. It is remarkable that we have not seen a scatterplot showing the association between amyloid reduction and cognitive outcomes in the donanemab or lecanemab studies. The pro
COMMENT I think this paper is helpful in putting some biomarker and neuropathology heft behind the growing consensus in the field that E4 homozygosity, in European ancestry individuals at least, is all but deterministic for the development of Alzheimer’s disease
COMMENT While it is encouraging to see alternative hypotheses being generated from post hoc data analyses, I'm not certain the field has fully come to grips with the lack of correlation between amount of amyloid removal and clinical efficacy. This is certain
COMMENT This is a very solid paper (over 50 subjects per group) that shores up our understanding of where and when ApoE4 begins to exert its influence on Alzheimer’s disease (AD). Though the sample selection and methods differ to some degree, the findings are lar
COMMENT This is the second study in the last year to point to the risk of bradycardia in patients receiving cholinesterase inhibitors (see also Gill et al., 2009). I think the risk of bradycardia is decidedly underappreciated among clinicians as supported by what
COMMENT Analyses of resting-state connectivity constitute a rapidly growing subfield of functional brain imaging. This technique is particularly appealing when studying neuropsychiatric patients, any of whom have difficulty performing tasks in the scanner. Depend
COMMENT In a landmark functional imaging paper (1), Marc Raichle described a network of brain regions, featuring the posterior cingulate cortex, medial prefrontal cortex, and temporoparietal junctions, whose activity decreased during the performance of externally
